TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025Treatment ...

Understanding what depression is – and what it is not – is often the first step toward relief.

Real-world data suggest GLP-1 receptor agonists may reduce emergency care visits and the need for additional migraine treatments in adults with chronic migraine.

In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with durable pain reduction and significant improvements in all key secondary ...

I'm a 68-year-old man and I'm suffering with hot flushes. Sometimes I get as many as 15 a day, often during the night. What ...

Adults with chronic migraine using glucagon-like peptide-1 receptor agonists for other conditions are seeking less migraine ...

A preliminary study conducted by researchers in Brazil and the United States suggests that GLP-1 medications used for weight ...

Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the ...

Neuropathic pain is a devastating type of pain that significantly reduces the quality of life of affected people.

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency ...

Chronic migraine patients taking glucagon-like peptide-1 drugs showed lower emergency care use and reduced need for ...

Preliminary study finds GLP-1 drugs (semaglutide, etc.) are associated with 10% fewer emergency visits and lower medication use for chronic migraine patients.